R&D: Cancer Gene Diagnostic Biochip/kitVisgeneer has been awarded with SBIR grant（Project Number: 1Z950428; Project name: The study of carcinogenic mechanism of T cell lymphoblastic lymphoma）and also has been awarded patents [Human Protein Phosphatase with EF-HANDS-1(PPEF-1)- Related Gene Variant Associated with T-Cell Lymphoblastic Lymphoma] in different countries (EU: 1903109B1; UK: 1903109; Germany. 602006012840.1-08; Netherlands: 1903109; France: 1903109; Spain: 1903109; Italy: 1903109). Visgeneer also has another patent (Human Ron-Related Gene Variant Associated with Cancers) in different countries (EU: 1892291B1; Germany. 602006021742.0-08; USA: 7,452,985B2；7,902,347B2；7,977,470B2). Based on our patent, the lymphoma nucleotide probe was immobilized on the biochip to develop lymphoma diagnostic biochip.
↑ Lymphoma diagnostic biochip
The picture showed that positive results were found on the reactions between cDNA obtained from T cell lymphoblastic lymphoma and the immobilized lymphoma nucleotide probes. To determine if the results were accurate, both positive control (GAPDH gene) and negative control were provided, respectively. This biochip was developed for use by health professionals in diagnosis of T cell lymphoblastic lymphoma.
